FOR IMMEDIATE RELEASE
AUGUST 6, 2019 ANN ARBOR, MI
Genomenon, Inc., the leading genomic search engine company, announced today that it was awarded a grant by the National Institutes of Health. The Small Business Innovation Research (SBIR) grant, awarded by the National Human Genome Research Institute*, will fund Genomenon’s further innovation in automating aspects of genomic interpretation from the research literature, and the creation of a platform for producing and sharing “micropublications” across the genomics community.
Micropublications are designed to rapidly place research findings and reviews in the public domain. Curated genomic variant interpretation can be made more efficient if findings and reviews can be rapidly published and shared across the research and clinical community. The grant funds Genomenon’s work to automatically organize the information relevant to genomic classification, along with conclusive content from scientific references, publish the findings, and share the information in a public format.
Importantly, the aim is to allow users to modify and keep up to date the micropublication as new research is published in the field so the findings are always up to date.
“This grant allows us to build on the work from our last successful NIH funding to increase the automation of variant interpretation and allow users to rapidly share their findings across the scientific community.” said Genomenon’s Co-founder and CSO, Dr. Mark Kiel. “This automated micropublication platform will help accelerate the sharing of knowledge as more and more genomic research is being published every year.
* Research reported in this publication was supported by the National Human Genome Research Institute of the National Institutes of Health under Award Number R43HG010446. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
The Real-world Evidence to validate a drug target, identify trial-eligible patients, or change a diagnosis already exists. It is buried in 39 million biomedical articles, locked behind paywalls and supplemental files most researchers never find.
Genomenon closes that gap. Fit-for-purpose AI-powered search reads 11.2 million full-text papers and 3.7 million supplemental datasets. Eighty expert scientific curators validate every finding. The result is structured, traceable, regulatory-grade Real-World Evidence at the genetic variant and patient level. Loxo@Lilly used Genomenon to add 73 variants to the RET label. In a head-to-head, Genomenon identified 83% more rare disease patients than ChatGPT plus OpenEvidence.
250+ diagnostic labs and 75 biopharma programs rely on Genomenon as the evidence layer behind precision medicine.
